These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 39341888)

  • 1. The chromatin landscape of high-grade serous ovarian cancer metastasis identifies regulatory drivers in post-chemotherapy residual tumour cells.
    Croft W; Pounds R; Jeevan D; Singh K; Balega J; Sundar S; Williams A; Ganesan R; Kehoe S; Ott S; Zuo J; Yap J; Moss P
    Commun Biol; 2024 Sep; 7(1):1211. PubMed ID: 39341888
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chromatin H3K27me3/H3K4me3 histone marks define gene sets in high-grade serous ovarian cancer that distinguish malignant, tumour-sustaining and chemo-resistant ovarian tumour cells.
    Chapman-Rothe N; Curry E; Zeller C; Liber D; Stronach E; Gabra H; Ghaem-Maghami S; Brown R
    Oncogene; 2013 Sep; 32(38):4586-92. PubMed ID: 23128397
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell surface CD55 traffics to the nucleus leading to cisplatin resistance and stemness by inducing PRC2 and H3K27 trimethylation on chromatin in ovarian cancer.
    Bharti R; Dey G; Khan D; Myers A; Huffman OG; Saygin C; Braley C; Richards E; Sangwan N; Willard B; Lathia JD; Fox PL; Lin F; Jha BK; Brown JM; Yu JS; Dwidar M; Joehlin-Price A; Vargas R; Michener CM; Longworth MS; Reizes O
    Mol Cancer; 2024 Jun; 23(1):121. PubMed ID: 38853277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.
    Koti M; Siu A; Clément I; Bidarimath M; Turashvili G; Edwards A; Rahimi K; Mes-Masson AM; Squire JA
    Br J Cancer; 2015 Mar; 112(7):1215-22. PubMed ID: 25826225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nuclear orphan receptor NR2F6 confers cisplatin resistance in epithelial ovarian cancer cells by activating the Notch3 signaling pathway.
    Li H; Zhang W; Niu C; Lin C; Wu X; Jian Y; Li Y; Ye L; Dai Y; Ouyang Y; Chen J; Qiu J; Song L; Zhang Y
    Int J Cancer; 2019 Oct; 145(7):1921-1934. PubMed ID: 30895619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Keratin 5 overexpression is associated with serous ovarian cancer recurrence and chemotherapy resistance.
    Ricciardelli C; Lokman NA; Pyragius CE; Ween MP; Macpherson AM; Ruszkiewicz A; Hoffmann P; Oehler MK
    Oncotarget; 2017 Mar; 8(11):17819-17832. PubMed ID: 28147318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single-cell RNA sequencing reveals that MYBL2 in malignant epithelial cells is involved in the development and progression of ovarian cancer.
    Shao W; Lin Z; Xiahou Z; Zhao F; Xu J; Liu X; Cai P
    Front Immunol; 2024; 15():1438198. PubMed ID: 39136009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adipocyte pyroptosis occurs in omental tumor microenvironment and is associated with chemoresistance of ovarian cancer.
    Lin CN; Liang YL; Tsai HF; Wu PY; Huang LY; Lin YH; Kang CY; Yao CL; Shen MR; Hsu KF
    J Biomed Sci; 2024 Jun; 31(1):62. PubMed ID: 38862973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chromatin accessibility changes at intergenic regions are associated with ovarian cancer drug resistance.
    Gallon J; Loomis E; Curry E; Martin N; Brody L; Garner I; Brown R; Flanagan JM
    Clin Epigenetics; 2021 Jun; 13(1):122. PubMed ID: 34090482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genes Predisposed to DNA Hypermethylation during Acquired Resistance to Chemotherapy Are Identified in Ovarian Tumors by Bivalent Chromatin Domains at Initial Diagnosis.
    Curry E; Zeller C; Masrour N; Patten DK; Gallon J; Wilhelm-Benartzi CS; Ghaem-Maghami S; Bowtell DD; Brown R
    Cancer Res; 2018 Mar; 78(6):1383-1391. PubMed ID: 29339543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy-Induced Distal Enhancers Drive Transcriptional Programs to Maintain the Chemoresistant State in Ovarian Cancer.
    Shang S; Yang J; Jazaeri AA; Duval AJ; Tufan T; Lopes Fischer N; Benamar M; Guessous F; Lee I; Campbell RM; Ebert PJ; Abbas T; Landen CN; Difeo A; Scacheri PC; Adli M
    Cancer Res; 2019 Sep; 79(18):4599-4611. PubMed ID: 31358529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer.
    Kanlikilicer P; Bayraktar R; Denizli M; Rashed MH; Ivan C; Aslan B; Mitra R; Karagoz K; Bayraktar E; Zhang X; Rodriguez-Aguayo C; El-Arabey AA; Kahraman N; Baydogan S; Ozkayar O; Gatza ML; Ozpolat B; Calin GA; Sood AK; Lopez-Berestein G
    EBioMedicine; 2018 Dec; 38():100-112. PubMed ID: 30487062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cross‑validation of genes potentially associated with neoadjuvant chemotherapy and platinum‑based chemoresistance in epithelial ovarian carcinoma.
    Zhang K; Wang W; Chen L; Liu Y; Hu J; Guo F; Tian W; Wang Y; Xue F
    Oncol Rep; 2020 Sep; 44(3):909-926. PubMed ID: 32705213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of the IGF1/PI3K/NF κB/ERK gene signalling networks associated with chemotherapy resistance and treatment response in high-grade serous epithelial ovarian cancer.
    Koti M; Gooding RJ; Nuin P; Haslehurst A; Crane C; Weberpals J; Childs T; Bryson P; Dharsee M; Evans K; Feilotter HE; Park PC; Squire JA
    BMC Cancer; 2013 Nov; 13():549. PubMed ID: 24237932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoxia-induced up-regulation of miR-27a promotes paclitaxel resistance in ovarian cancer.
    Feng L; Shen F; Zhou J; Li Y; Jiang R; Chen Y
    Biosci Rep; 2020 Apr; 40(4):. PubMed ID: 32190895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma.
    Brachova P; Mueting SR; Carlson MJ; Goodheart MJ; Button AM; Mott SL; Dai D; Thiel KW; Devor EJ; Leslie KK
    Int J Oncol; 2015 Feb; 46(2):607-18. PubMed ID: 25385265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ovarian high-grade serous carcinoma cells with low SMARCA4 expression and high SMARCA2 expression contribute to platinum resistance.
    Kido K; Nojima S; Motooka D; Nomura Y; Kohara M; Sato K; Ohshima K; Tahara S; Kurashige M; Umeda D; Takashima T; Kiyokawa H; Ukon K; Matsui T; Okuzaki D; Morii E
    J Pathol; 2023 May; 260(1):56-70. PubMed ID: 36763038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel cell line panel reveals non-genetic mediators of platinum resistance and phenotypic diversity in high grade serous ovarian cancer.
    Hoare JI; Hockings H; Saxena J; Silva VL; Haughey MJ; Wood GE; Nicolini F; Mirza H; McNeish IA; Huang W; Maniati E; Graham TA; Lockley M
    Gynecol Oncol; 2022 Oct; 167(1):96-106. PubMed ID: 35918200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-7 expression in serous ovarian carcinomas.
    Swiercz A; Chechlinska M; Kupryjanczyk J; Dansonka-Mieszkowska A; Rembiszewska A; Goryca K; Kulinczak M; Zajdel M; Sromek M; Siwicki JK
    Anticancer Res; 2015 Apr; 35(4):2423-9. PubMed ID: 25862909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.